Agreed. Once it becomes a priority with the subsequent funding/grants, I think that's when we'd see movement. Ironically, however, I wonder if the hype around the current program even slows adoption of new priorities.
Though, perhaps acknowledgments such as the type referenced by public health officials in this article portend the start of some movement.
>left without a chair when the current gravy train ends when better vaccines are deployed
I wonder if their thinking is that this problem is easily fixed through acquisition if/when the time comes, especially in an industry as M & A-driven as pharma. Meanwhile, gravy-train.
Agreed. Once it becomes a priority with the subsequent funding/grants, I think that's when we'd see movement. Ironically, however, I wonder if the hype around the current program even slows adoption of new priorities.
Though, perhaps acknowledgments such as the type referenced by public health officials in this article portend the start of some movement.
>left without a chair when the current gravy train ends when better vaccines are deployed
I wonder if their thinking is that this problem is easily fixed through acquisition if/when the time comes, especially in an industry as M & A-driven as pharma. Meanwhile, gravy-train.